Does IgA antibody against β2 glycoprotein I increase cardiovascular risk in hemodialysis patients?
Cardiovascular disease is the most common cause of mortality in patients with chronic kidney disease on hemodialysis. In addition to a high prevalence of traditional cardiovascular risk factors, other specific factors, including uremia and chronic inflammation, seem to contribute to the excess cardiovascular mortality. The findings of Serrano et al. point to a link between IgA antibodies against β2 glycoprotein I and cardiovascular events in renal dialysis patients.
Rajesh K
RK
Patel
Roopen
R
Arya
D001323:Autoantibodies / Q000097:blood*; D002318:Cardiovascular Diseases / Q000401:mortality*; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D006435:Renal Dialysis / Q000401:mortality*; D053482:beta 2-Glycoprotein I / Q000276:immunology*
D001323:Autoantibodies; D007070:Immunoglobulin A; D053482:beta 2-Glycoprotein I